InstellingenIk ga akkoord



9th Call IMI published

The JTI Innovative Medicines Initiative (IMI) has published the 9th Call for proposals. The closing date is October 9, 2013. The Call includes topics covering the following key research priorities: Knowledge Management (correlated to the area of interest: Knowledge, Patient, Development), Coping with Regulatory and Legal Hurdles (correlated to the area of interest: Development), Beyond Drug Discovery: Drug Development and the Regulatory Framework (correlated to the area of interest: Development) and Infectious diseases (correlated to the area of interest: Disease Drug Efficacy). The indicative in kind contribution from the research-based companies that are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) is € 72.25 million. The financial contribution from the European Community to the IMI JU for the support of research activities will be up to € 63.12 million.

The Innovative Medicines Initiative (IMI) is Europe's largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in Europe that will boost innovation in healthcare. Acting as a neutral third party in creating innovative partnerships, IMI aims to build a more collaborative ecosystem for pharmaceutical research and development (R&D). IMI will provide socio-economic benefits to European citizens, increase Europe's competitiveness globally and establish Europe as the most attractive place for pharmaceutical R&D.

Terug naar overzicht